Fly News Breaks for December 17, 2015
ALIM, PSDV
Dec 17, 2015 | 14:48 EDT
Northland analyst Suraj Kalia noted the Reuters report that Alimera Sciences (ALIM), a licensee of pSivida (PSDV), is exploring strategic alternatives. If Alimera get bought, the acquirer could keep its current contractual arrangement with pSivida, under which it is entitled to 20% of "net profits" on sales of Iluvien in DME, in place, or could try to negotiate an upfront lump sum payment to pSivida for Iluvien, the analyst stated. Kalia keeps an Outperform rating and $10 price target on pSivida shares.
News For PSDV;ALIM From the Last 2 Days